Skip to main content

Table 4 MS prevalence by BMI, gender and clinical lipodystrophy according to ATPIII criteria and IDF

From: Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

  Men Women
  Without CL With CL Without CL With CL
ATPIII criteria
Classes of BMI
[kg/m2; (n (%)]
    
< 25 14 (30.4%) 41 (48.8%) 3 (12.5%) 11 (44.0%)
≥25 < 30 19 (41.3%) 33 (39.3%) 9 (37.5%) 10 (40.0%)
≥30 13 (28.3%) 10 (11.9%) 12 (50.0%) 4 (16.0%)
p value 0.002 < 0.001 0.012 0.008
IDF criteria
< 25 4 (11.1%) 11 (21.2%) 5 (18.5%) 16 (48.5%)
≥25 < 30 18 (50.0%) 32 (61.5%) 10 (37.0%) 13 (39.4%)
≥30 14 (38.9%) 9 (17.3%) 12 (44.4%) 4 (12.1%)
p value < 0.001 < 0.001 0.084 0.012
  1. Note - CL = Clinical lipodystrophy; MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; BMI = body mass in